AG126 是一种酪氨酸激酶抑制剂，在 25-50 μM 时可抑制ERK1和ERK2的磷酸化。AG126 可用于减数分裂、有丝分裂和有丝分裂后的研究。
| 生物活性 | AG126 is atyrosine kinase inhibitor, can inhibit the phosphorylation ofERK1andERK2at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research[1][2][3][4]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | AG126 (10 μM; overnight) increases the viability of ARPE-19 cells[2].
AG126 at concentrations higher than 10 μM show toxic to ARPE-19 cells and can enhance H2O2toxicity[2].
AG126 (0.1-100 μM) inhibits VEGF-induced proliferation of BRMECs[4].
Cell Viability Assay[2] | Cell Line: | ARPE-19 cells | | Concentration: | 10 μM | | Incubation Time: | Overnight | | Result: | Increased the viability of ARPE-19 cells to 35-72% compared to the control. |
Cell Proliferation Assay[4] | Cell Line: | BRMECs | | Concentration: | 0.1-100 μM | | Incubation Time: | | | Result: | Inhibited VEGF-induced proliferation of BRMECs in a dose-dependent manner. |
|
体内研究
(In Vivo) | AG 126 (intraperitoneal injection; 1-10 mg/kg; 1 h and 6 h after Zymosan treatment) treatment attenuates the degree of multiple organ failure (MOF) associated with Zymosan-induced peritonitis in the rat[3].
| Animal Model: | Male Sprague-Dawley rats treated with Zymosan (500 mg/kg)[3] | | Dosage: | 10 mg/kg, 3 mg/kg or 1 mg/kg | | Administration: | Intraperitoneal injection; 10, 3, or 1 mg/kg; 1 h and 6 h after Zymosan treatment | | Result: | Attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by Zymosan in a dose-dependent fashion.
Attenuated the lung, liver, and intestinal injury.
Reduced the production of peroxynitrite and of pro-inflammatory cytokines TNF-alpha and IL-1beta. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(464.75 mM;Need ultrasonic and warming) 配制储备液 | 1 mM | 4.6475 mL | 23.2374 mL | 46.4749 mL | | 5 mM | 0.9295 mL | 4.6475 mL | 9.2950 mL | | 10 mM | 0.4647 mL | 2.3237 mL | 4.6475 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (11.62 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (11.62 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com